Ascendis Pharma ASMEX:ASNDN 37 PB Ratio is 23.24 as of Jun. 25, 2026, which is 8% below its 10-year median of 25.20. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Ascendis Pharma AS ranks worse than 94.81% on this metric.
The historical rank and industry rank for Ascendis Pharma AS's PB Ratio or its related term are showing as below:
MEX:ASNDN'
s PB Ratio Range Over the Past 10 Years
Min: 23.05 Med: 25.2 Max: 27.06
Current: 26.03
During the past 13 years, Ascendis Pharma AS's highest PB Ratio was 27.06. The lowest was 23.05. And the median was 25.20.
MEX:ASNDN's PB Ratio is ranked worse than 94.81% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs MEX:ASNDN: 26.03
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ascendis Pharma AS was 470.10% per year. The lowest was -29.30% per year. And the median was 34.00% per year.
Back to Basics: PB Ratio
Ascendis Pharma AS (MEX:ASNDN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ascendis Pharma AS PB Ratio Related Terms
Ascendis Pharma AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ASNDN vs SMMT, BBIO, JAZZ: PB Ratio Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ascendis Pharma AS (MEX:ASNDN) has a PB Ratio of 23.24 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ascendis Pharma AS and its competitors. This is near median its historical median of 25.20. Over the past decade, Ascendis Pharma AS's PB Ratio has ranged from 23.05 to 27.06. According to the industry distribution chart, Ascendis Pharma AS ranks #1169 out of 1233 companies in the Biotechnology industry, placing it in the top 94.8%.
Is Ascendis Pharma AS's PB Ratio too high?
Ascendis Pharma AS's current PB Ratio of 23.24 is near median its 10-year median of 25.20. Over the past 10 years, this metric has ranged from a low of 23.05 to a high of 27.06. The Biotechnology industry median PB Ratio is 2.80. Ascendis Pharma AS's value of 23.24 is 730% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #1169 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's PB Ratio compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #1169 out of 1233 companies for PB Ratio. This places Ascendis Pharma AS in the lower half of its industry. The industry median PB Ratio is 2.80. Ascendis Pharma AS's value of 23.24 is 730% above this benchmark. Historically, Ascendis Pharma AS's own PB Ratio has ranged from 23.05 to 27.06 over the past decade. While the company's 10-year median is 25.20 vs. the industry median of 2.80, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current PB Ratio of 23.24 is 730% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current PB Ratio is 23.24, which is near median its own 10-year median of 25.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current PB Ratio of 23.24. The current PB Ratio is 23.24, which is near median its 10-year median of 25.20 and 730% above the Biotechnology industry median of 2.80. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current PB Ratio is 23.24 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
